FDA Accepts Priority Review Of Biologics License Application For ltragenyx Pharmaceutical's DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia

Ultragenyx Pharmaceutical, Inc. -1.56% Post

Ultragenyx Pharmaceutical, Inc.

RARE

21.46

21.46

-1.56%

0.00% Post

If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via